Rickets and osteoporosis

Pediatric Endocrinology, Fifth Edition: Volume 2 Growth, Adrenal, Sexual, Thyroid, Calcium, and Fluid Balance Disorders

Volumn , Issue , 2006, Pages 531-557

  Plotkin, Horacio ^a   Lifshitz, Fima ^b,c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250870475     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (357)

1. Plotkin H. Syndromes with congenital brittle bones. BioMed Central Pediatr 2004; 4:16.
2. Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Int Med 1978; 89:966-982.
3. Pettifor J. Nutritional rickets. In: Glorieux FH, Pettifor JM, Jueppner H, eds. Pediatric Bone: Biology and Diseases. San Diego: Academic Press, 2003:541-565.
4. Wharton B, Bishop N. Rickets. Lancet 2003; 25:1389-1400.
5. Krieter SR, Schwarts RP, Kirkman HN, Charlton PA, Calikoglu AS, Davenport ML. Nutritional rickets in African-American breast fed infants. J Pediatr 2000; 137:153-157.
6. Curran JS, Barness LA. Nutrition. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson’s Textbook of Pediatrics. 16th. Philadelphia, W.B: Saunders, 2000:155-156.
7. Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child 1985; 139:1134-1137.
8. Specker BL, Tsang RC. Cyclical serum 25-hydroxyvitamin D concentrations paralleling sunshine exposure in exclusively breast-fed infants. J Pediatr 1987; 110:744-747.
9. Waiters B, Godel JC, Basu TK. Perinatal vitamin D and calcium status of northern Canadian mothers and their newborn infants. J Am Coll Nutr 1998; 18:122-126.
10. Canadian Pediatric Society. Vitamin D supplementation for northern native communities. Can Med Assoc J 1988; 138:229-231.
11. Gartner LM, Greer FR. Prevention of rickets and vitamin D deficiency: new guidelines for vitamin D intake. Pediatrics 2003; 111:908-909.
12. Anatoliotaki M, Tsilimigaki A, Tsekoura T, Schinaki A, Stefanaki S, Nikolaidou P. Congenital rickets due to maternal vitamin D deficiency in a sunny island of Greece. Acta Paediatrica 2003; 92:389-391.
13. Delvin EE, Salle BL, Glorieux FH, Adeleine P, David LS. Vitamin D supplementation during pregnancy: effect on neonatal calcium homeostasis. J Pediatr 1986; 109:328-334.
14. Lifshitz F, Maclaren N. Vitamin D dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy. I. A survey of 288 patients. J Pediatr 1973; 83:612-620.
15. Hahn TJ, Hendin BA, Scharp CR, Haddad JGJ. Effect of chronic anticonvulsant therapy on serum 25-hydroxycholecalciferol levels in adults. N Engl J Med 1972; 287:900-904.
16. Hahn TJ, Hendin BA, Scharp CR, Boisseau VC, Haddad JGJ. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 1975; 292:550-554.
17. Maclaren N, Lifshitz F. Vitamin D dependency rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy. II. The response to 25-hydroxycholechalciferol and to vitamin D2. Pediatr Res 1973; 7:914-922.
18. Bischoff F, Basu D, Pettifor JM. Pathological long-bone fractures in residents with cerebral palsy in a long-term care facility in South Africa. Dev Med Child Neurol 2002; 44:119-122.
19. Henderson RC, Lin PP, Greene WB. Bone-mineral density in children and adolescents who have spastic cerebral palsy. J Bone Joint Surg Am 1995; 77:1671-1681.
20. Jubiz W, Haussler MR, McCain TA, Tolman KG. Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 1977; 44:617-621.
21. Ala-Houhala M, Korpela R, Koivikko M, Koskinen T, Koskinen M, Koivula T. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics 1986; 17:212-216.
22. Vieth R, Fraser D. Vitamin D insufficiency: no recommended dietary allowance exists for this nutrient. CMAJ 2002; 166:1541-1542.
23. http://www.NAL.USDA.cou/PNIC/ETEXT/000105.
24. HolickMF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(suppl):1678S-1688S.
25. Norman AW, Roth J, Orci L. The vitamin D endocrine system: steroid metabolism, hormone receptors and biological response (calcium binding proteins). Endocr Rev 1982; 3:331-366.
26. Horst RL, Reinhardt TA. Vitamin D metabolism. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego: Academic Press, 1997:13-31.
27. Chesney RW, Zimmerman J, Hamstra A, DeLuca HF, Mazees RB. Vitamin D metabolite concentrations in vitamin D deficiency. Are calcitriol levels normal? Am J Dis Child 1981; 135:1025-1028.
28. Compston JE, Vedi S, Merrett AL, Clemens TL, O’Riordan JL, Woodhead JS. Privational and malabsorption metabolic bone disease: plasma vitamin D metabolite concentrations and their relationship to quantitative bone histology. Metab Bone Dis Relat Res 1981; 3:165-170.
29. Parfitt AM. Vitamin D and the pathogenesis of rickets and osteomalacia. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego: Academic Press, 1997:645-662.
30. Board IoMFaN. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, D.C.: National Academy Press, 1999.
31. Nordin BE. Calcium requirement is a sliding scale. Am J Clin Nutr 2000; 71:1381-1383.
32. Lanou AJ, Berkow SE, Barnard NE. Calcium, dairy products, and bone health in children and young adults: a reevaluation of the evidence. Pediatrics 2005; 115:736-743.
33. Zhu K, Du X, Cowell CT. Effects of school milk intervention on cortical bone accretion and indicators relevant to bone metabolism in Chinese girls aged 10-12y in Beijing. Am J Clin Nutr 2005; 81:1168-1171.
34. Popkin BM, Armstrong LE, Bray GM, Caballero B, Frei B, Willett WC. A new proposed guidance system for beverage consumption in the United States. Am J Clin Nutr 2006; 83:529-542.
35. Lloyd T, Petit MA, Lin HM, Beck TJ. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr 2004; 144:776-782.
36. Rowlands AV, Ingledew DK, Powell SM, Eston RG. Interactive effects of habitual physical activity and calcium intake on bone density in boys and girls. J Appl Physiol 2004; 97:1203-1208.
37. Holick MF. Photosynthesis, metabolism, and biologic actions of vitamin D. In: Glorieux FH, ed. Rickets. New York: Raven Press, 1991:1-20.
38. Kruse K. Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. J Pediatr 1995; 126:736-741.
39. Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr 1994; 125:487-490.
40. Prader VA, Illig R, Heierli E. Eine besondere form der primaren vitamin-D-resistenten rachitis mit hypocalcamie und autosomal-dominantem erbang: Die hereditare pseudomangelrachitis. Helv Paediatr Acta 1961; 16:452-468.
41. Fraser D, Kooh SW, Kind HP, Hollick MF, Tanaka Y, DeLuca HF. Pathogenesis of hereditary vitaminDdependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1alpha,25-dihydroxyvitamin D. N Engl J Med 1973; 289:817-822.
42. Fu GK, Lin D, Zhang MY, et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997; 11:1961-1970.
43. Aarskog D, Aksnes L, Markestad T. Effect of parathyroid hormone on cAMP and 1,25-dihydroxyvitamin D formation and renal handling of phosphate in vitamin D-dependent rickets. Pediatrics 1983; 71:59-63.
44. Scriver CR. Vitamin D dependency. Pediatrics 1970; 45:361-363.
45. Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338:653-661.
46. Portale AA, Miller WL. Rickets due to hereditary abnormalities of vitamin D synthesis or action. In: Glorieux FH, Pettifor J, Jueppner H, eds. Pediatric Bones: Biology and Diseases. San Diego: Academic Press, 2003:583-601.
47. Stoop JW, Schraagen MJ, Tiddens HA. Pseudo vitamin D deficiency rickets. Report of four new cases. Acta Paediatr Scand 1967; 56:607-616.
48. Arnaud C, Maijer R, Reade T, Scriver CR, Whelan DT. Vitamin D dependency: an inherited postnatal syndrome with secondary hyperparathyroidism. Pediatrics 1970; 46:871-880.
49. Scriver CR, Reade TM, DeLuca HF, Hamstra AJ. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978; 299:976-979.
50. Wang JT, Lin CJ, Burridge SM, et al. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet 1998; 63:1694-1702.
51. Kitanaka S, Murayama A, Sakaki T, et al. No enzyme activity of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 1999; 84:4111-4117.
52. Delvin EE, Glorieux FH, Marie PJ, Pettifor JM. Vitamin-D dependency: replacement therapy with calcitriol. J Pediatr 1981; 99:26-34.
53. Casella SJ, Reiner BJ, Chen TC, Hollick MF, Harrison HE. A possible genetic defect in 25-hydroxylation as a cause of rickets. J Pediatr 1994; 124:929-932.
54. Brooks MH, Bell NH, Love L, et al. Vitamin D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978; 298:996-999.
55. Marx SJ, Spiegel AM, Brown EM, et al. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1978; 47:1303-1310.
56. Malloy PJ, Hochberg Z, Tiosano D, Pike JW, Hughes MR, Feldman D. The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. J Clin Invest 1990; 86:2071-2079.
57. Liberman UA, Eil C, Marx SJ. Resistance of 1,25 dihydroxyvitamin D associated with heterogeneous defects in cultured skin fibroblasts. J Clin Invest 1983; 71:192-200.
58. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13:325-349.
59. Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85:3294-3298.
60. Szpirer J, Szpirer C, Riviere M, et al. The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics 1991; 11:168-173.
61. Fraher LJ, Karmali R, Hinde FR, et al. Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D3 in a patient without alopecia. Eur J Pediatr 1986; 145:389-395.
62. Liberman UA, Samuel R, Halabe A, et al. End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet 1980; 1: 504-506.
63. Chen TL, Hirst MA, Cone CM, Hochberg Z, Tietze HU, Feldman D. 1,25-dihydroxyvitamin D resistance, rickets, and alopecia: analysis of receptors and bioresponse in cultured fibroblasts from patients and parents. J Clin Endocrinol Metab 1984; 59:383-388.
64. Hughes MR, Malloy PJ, Kieback DG, et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988; 242:1702-1705.
65. Malloy PJ, Hochberg Z, Pike JW, Feldman D. Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab 1989:263-269.
66. Rummens K, Van Cromphaut SJ, Carmeliet G, et al. Pregnancy in mice lacking the vitamin D receptor: normal maternal skeletal response, but fetal hypomineralization rescued by maternal calcium supplementation. Pediatr Res 2003.
67. Malloy PJ, Xu R, Cattani A, Reyes ML, Feldman D. A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res 2004; 19:1018-1024.
68. Malloy PJ, Xu R, Peng L, Clark PA, Feldman D. A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol Endocrinol 2002; 16:2538-2546.
69. Marx SJ, Bliziotes MM, Nanes M. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D. Clin Endocrinol (Oxf) 1986; 25:373-381.
70. Whitfield GK, Selznick SH, Haussler CA, et al. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol 1996; 10:1617-1631.
71. Malloy PJ, Xu R, Peng L, Peleg S, Al-Ashwal A, Feldman D. Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology 2004; 145(11):5106-5114.
72. al-Aqeel A, Ozand P, Sobki S, Sewairi W, Marx S. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol (Oxf) 1993; 39:229-237.
73. Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J Pediatr 1992; 121:803-808.
74. Albright F, Butler AM, Bloomberg E. Rickets resistant to vitamin D therapy. Am J Dis Child 1937; 54:529-547.
75. Batra P, Tejani Z, Mars M. X-linked hypophosphatemia: dental and histologic findings. J Can Dent Assoc 2006; 72: 69-72.
76. Goji K, Ozaki K, Sadewa AH, Nishio H, Matsuo M. Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait. J Clin Endocrinol Metab 2006; 91:365-370.
77. Tenenhouse HS. Metabolism of 25-hydroxyvitamin D3 in renal slices from the X-linked hypophosphatemic (Hyp) mouse: abnormal response to fall in serum calcium. Cell Calcium 1984; 5:43-55.
78. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68(3):1148-1153.
79. Consortium A. Autosomal dominant hypohposphatemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348.
80. Prie D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347:983-991.
81. Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 1971; 7:287-295.
82. Econs MJ, McEnery PT, Lennon F, Speer MC. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997; 100:2653-2657.
83. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505.
84. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
85. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35:455-462.
86. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 2005; 58:329-333.
87. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:642-646.
88. Kronenberg H. NPT2a-the key to phosphate homeostasis. N Engl J Med 2002; 347:1022-1024.
89. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78:193-201.
90. Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodiumphosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179-192.
91. Harrison HE, Lifshitz F, Blizzard RM. Comparison between crystalline dihydrotachysterol and calciferol in patients requiring pharmacologic vitamin D therapy. N Engl J Med 1967; 276:694-700.
92. Harrison HE, Harrison HC, Lifshitz F, Johnson AD. Growth disturbance in hereditary hypophosphatemia. Am J Dis Child 1966; 112:290-297.
93. Seikal MG, Browne RH, Baum M. The effect of phosphate supplementation on linear growth in children with Xlinked hypophosphatemia. Pediatrics 1994; 94:478-481.
94. Friedman NE, Lobaugh B, Drezner MK. Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1993; 76:839-844.
95. Novais E, Stevens PM. Hypophosphatemic rickets: the role of hemiepiphysiodesis. J Pediatr Orthop 2006; 26:238-244.
96. McCrance RA. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquiredabout the age of15years.Quat JMed1947; 16:33-46.
97. Sparagana M. Tumor-induced osteomalacia: long-term follow-up of two patients cured by removal of their tumors. J Surg Oncol 1987; 36:198-205.
98. Aschinberg LC, Solomon LM, Zeis PM, Justice P, Rosenthal IM. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 1977; 91:56-60.
99. Carey DE, Drezner MK, Hamdan JA, et al. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia. J Pediatr 1986; 109:994-1000.
100. Lyles KW, Berry WR, Haussler M, Harrelson JM, Drezner MK. Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med 1980; 93:275-278.
101. Colman P, Firkin BG, van der Weyden MB. Severe hypophosphataemia in T-cell lymphoblastic lymphoma. Br Med J (Clin Res Ed) 1983; 8:105-106.
102. Sartori L, Weir EC, Stewart AF, et al. Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line. J Clin Endocrinol Metab 1988; 66:459-461.
103. Chalew SA, Lovchik JC, Brown CM, Sun CC. Hypophosphatemia induced in mice by transplantation of a tumorderived cell line from a patient with oncogenic rickets. J Pediatr Endocrinol Metab 1996; 9:593-597.
104. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414.
105. Firth RG, Grant CS, Riggs BL. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases. Am J Med 1985; 78:669-673.
106. Parker MS, Klein I, Haussler MR, Mintz DH. Tumorinduced osteomalacia. Evidence of a surgically correctable alteration in vitamin D metabolism. JAMA 1981; 245:492-493.
107. Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 1997; 12:1502-1511.
108. Murer H, Hernando N, Foster I, Biber J. Proximal tubular reabsorption of phosphate: molecular mechanisms. Physiol Rev 2000; 80:1373-1409.
109. Kempson SA, Lotscher M, Kaissling B, Bibere J, Murer H, Levi M. Parathyroid hormone action on phosphate transporter mRNA and protein in renal proximal tubules. Am J Physiol 1995; 268:F784-F791.
110. Caswell AM, Whyte MP, Russell RGG. Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci 1992; 28:175-232.
111. Orimo H, Hayashi Z, Watanabe A, Hirayama T, Hirayama T, Shimada T. Novel missense and frameshift mutations in the tissue-nonspecific alkaline phosphatase gene in a Japanese patient with hypophosphatasia. Hum Molec Genet 1994; 3:1683-1684.
112. Orimo H, Goseki-Sone M, Sato S, Shimada T. Detection of deletion 1154-1156 hypophosphatasia mutation using TNSALP exon amplification. Genomics 1997; 42:364-366.
113. Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-50-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest 1985; 76:752-756.
114. WhyteMP. Hypophosphatasia. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th. Washington, D.C.: American Society for Bone and Mineral Research, 2003:423-425.
115. Whyte MP. Hypophosphatasia. In: Scriver CH, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th. New York: McGraw-Hill, 2001:5313-5329.
116. Shohat M, Rimoin DL, Gruber HE, Lachman RS. Perinatal lethal hypophosphatasia: clinical, radiological and morphological findings. Pediatr Radiol 1991; 21:421-427.
117. Moore CA, Ward JC, Rivas ML, Magill HL, Whyte MP. Infantile hypophosphatasia: autosomal recessive transmission to two related sibships. Am J Med Gentol 1990; 36:15-22.
118. Henthorn PS, Whyte MP. Missense mutations of the tissue-nonspecific alkaline phosphatase gene in hypophosphatasia. Clin Chem 1992; 38:2501-2505.
119. Henthorn PS, Whyte MP. Infantile hypophosphatasia: successful prenatal assessment by testing for tissue-nonspecific alkaline phosphatase gene mutations. Prenatal Diagn 1995; 15:1001-1006.
120. Greenberg CR, Evans JA, McKendry-Smith S, et al. Infantile hypophosphatasia: localisation within chromosome region 1p36.1-34 and prenatal diagnosis using linked DNA markers. Am J Hum Genet 1990; 46:286-292.
121. Scriver CR, Cameron D. Pseudohypophosphatasia.NEngl J Med 1969; 281:604-606.
122. Cole DE, Salisbury SR, Stinson RA, Coburn SP, Ryan LM, Whyte MP. Increased serum pyridoxal-50-phosphate in pseudohypophosphatasia. N Engl J Med 1986; 314: 992-993.
123. Mulivor RA, Mennuti M, Zuckai EH, Harris H. Prenatal diagnosis of hypophosphatasia: genetic, biochemical and clinical studies. Am J Hum Genet 1978; 30: 271-282.
124. Warren RC, McKenzie CF, Rodeck CH, Moscoso G, Brock DJ, Barron L. First trimester diagnosis of hypophosphatasia with a monoclonal antibody to the liver/bone/kidney isoenzyme of alkaline phosphatase. Lancet 1985; 2:856-858.
125. Whyte MP, Kurtzburg J, Gottesman GS, et al. Marked clinical and radiographic improvement in infantile hypophosphatasia transiently after haploidentical bone marrow transplantation. Bone 1998; 23(S5):S191.
126. Girschick HJ, Seyberth HW, Huppertz HI. Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs. Bone 1999; 25:603-607.
127. Haddad JGJ, Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab 1976; 42:284-290.
128. Thys-Jacobs S, Chan FKW, Koberle LMC, Bilezikian JP. Hypercalcemia due to vitamin D toxicity. In: Feldman F, ed. Vitamin D. San Diego: Academic Press, 1997:883-901.
129. Reinhardt TA, Horst RL. Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. Endocrinology 1990; 127:942-948.
130. Parfitt AM, Gallagher JC, Heaney RP, Johnston CC, Neer R, Whedon GD. Vitamin D and bone health in the elderly. Am J Clin Nutr 1982; 36(5 suppl):1014-1031.
131. Blum M, Kirsten M, Worth MHJ. Reversible hypertension. Caused by the hypercalcemia of hyperparathyroidism, vitamin D toxicity, and calcium infusion. JAMA 1977; 237:262-263.
132. Adams JS, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann Int Med 1997; 127:203-206.
133. Lee DC, Lee GY. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. J Toxicol Clin Toxicol 1998; 36:719-721.
134. Gurkan F, Davutoglu M, Bosnak M, et al. Pamidronate treatment in acute vitamin D intoxication. J Endocrinol Invest 2004; 27:680-682.
135. Schonau E. Problems of bone analysis in childhood and adolescence. Pediatr Nephrol 1998; 12:420-429.
136. Zionts LE, Nash JP, Rude R, Ross T, Stott NS. Bone mineral density in children with mild osteogenesis imperfecta. J Bone Joint Surg Br 1995; 77:143-147.
137. Mazess RB. Bone densitometry in infants. J Pediatr 1988; 113:188-195.
138. DePriester JA, Cole TJ, Bishop NJ. Bone growth and mineralisation in children aged 4 to 10 years. Bone Miner 1991; 12:57-65.
139. Trouerbach WT, de Man SA, Gommers D, Zwamborn AW, Grobbee DE. Determinants of bone mineral content in childhood. Bone Miner 1991; 13:55-67.
140. Plotkin H, Nunez M, Alvarez Filgueira ML, Zanchetta JR. Lumbar spine bone density in Argentine children. Calcif Tissue Int 1996; 58:144-149.
141. Plotkin H, Nuñ ez M, Alvarez Filgueira ML, Zanchetta JR. Factores determinantes de la densidad mineral ósea en una población argentina de 2 a 20 añ os de edad (Determinant factors of bone mineral density in argentine children 2-20 years of age). Arch Argent Pediat 1996; 94:14-20.
142. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7:137-145.
143. Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990; 70:1330-1333.
144. Zanchetta JR, Plotkin H, Alvarez Filgueira ML. Bone mass in children: normative values for the 2-20-year-old population. Bone 1995; 16(4 suppl):393S-399S.
145. Braillon PM, Cochat P. Analysis of dual energy X-ray absorptiometry whole body results in children, adolescents and young adults. Appl Radiat Isot 1998; 49:623-624.
146. Bailey DA. The Saskatchewan Pediatric Bone Mineral Accrual study: bone mineral acquisition during the growing years. Int J Sports Med 1997; 18(suppl 3):S191-S194.
147. Molgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997; 76:9-15.
148. Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA. Bone densitometry in Canadian children 8-17 years of Age. Calcif Tissue Int 1996; 59:344-351.
149. Nguyen TV, Maynard LM, Towne B, et al. Sex differences in bone mass acquisition during growth. J Clin Densit 2001; 4:147-157.
150. Plotkin H, Sawyer A, Bachrach L. Mind your “T’s” and “Z’s”. J Bone Joint Surg Am 2003; 85:1390-1391.
151. Schonau E, Rauch F. Markers of bone and collagen metabolism -problems and perspectives in paediatrics. Horm Res 1997; 48(suppl):50-59.
152. Seeman E, Young N, Szmukler G, Tsalamandris C, Hopper JL. Risk factors for osteoporosis. Osteoporos Int 1993; (suppl 1):s40-s43.
153. Kelly PJ, Eisman JA, Sambrook PN. Interaction of genetic and environmental influences on peak bone density. Osteoporos Int 1990; 1:56-60.
154. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos International 2000; 11:985-1009.
155. Matkovic V. Calcium and peak bone mass. J Intern Med 1992; 231(2):151-160.
156. Fitzpatrick LA, Heaney RP. Got soda? J Bone Miner Res 2003; 18:1570-1572.
157. Heaney RP. Dietary protein and phosphorus do not affect calcium absorption. Am J Clin Nutr 2000; 72:758-761.
158. Fitzpatrick LA. Does consumption of cola beverages cause bone fractures in children? Mayo Clin Proc 2002; 77:1005-1006.
159. Heaney RP, Dowell S, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001; 20:239-246.
160. Martin BR, Weaver CM, Heaney RP, Packard PT, Smith DL. Calcium absorption from three salts and CaSO(4)-fortified bread in premenopausal women. J Agric Food Chem 2002; 50:3874-3876.
161. Heaney RP. Calcium supplements: practical considerations. Osteoporos Int 1991; 1:65-71.
162. Heaney RP, Rafferty K, Dowell MS, Bierman J. Calcium fortification systems differ in bioavailability. J Am Diet Assoc 2005; 105:807-809.
163. Frost HM. Why the ISMNI and the Utah paradigm? Their role in skeletal and extraskeletal disorders. J Musculoskelet Neuronal Interact 2000; 1:5-9.
164. Jee WS. Principles in bone physiology. J Musculoskelet Neuronal Interact 2000; 1:11-13.
165. Recker R. Genetic research in osteoporosis: Where are we? Where should we go next? J Musculoskelet Neuronal Interact 2004; 4:86-90.
166. Klein R. Genetic regulation of bone mineral density in mice. J Musculoskelet Neuronal Interact 2002; 2:232-236.
167. Haara M, Heliovaara M, Impivaara O, et al. Low metacarpal index predicts hip fracture: a prospective population study of 3,561 subjects with 15 years of follow-up. Acta Orthop 2006; 77:9-14.
168. Bass M, Ford MA, Brown B, Mauromoustakos A, Keathley RS. Variables for the prediction of femoral bone mineral status in American women. South Med J 2006; 99:105-106.
169. Bidula J, Boehm C, Powell K, et al. Osteogenic progenitors in bone marrow aspirates from smokers and nonsmokers. Clin Orthop Relat Res 2006; 442:252-259.
170. Lorentzon M, Swanson C, Eriksson AL, Mellstrom D, Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J Bone Miner Res 2006; 21:332-339.
171. Bernat MM, Pasini J, Marekovic Z. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Coll Antropol 2005; 29:598-591.
172. Guang-Da X, Hui-Ling S, Zhi-Song C, Lin-Shuang Z. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. J Endocrinol Invest 2005; 28:965-972.
173. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581-589.
174. Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res 1998; 13:1337-1342.
175. Matkovic V, Fontana D, Tominac C, Goel P, Chesnut CHI. Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr 1990; 52:878-888.
176. Wosje KS, Specker BL. Role of calcium in bone health during childhood. Nutr Rev 2000; 58:253-258.
177. Dodiuk-Gad RP, Rozen S, Rennert G, Rennert HS, Ish-Shalom S. Sustained effect of short term calcium supplementation on bone mass in adolescents with low calcium intake. Am J Clin Nutr 2005; 81:168-174.
178. Matkovic V, Goel PK, Badenhop-Stevens NE, et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005; 81:175-18.
179. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE. Severe immobilisation-induced hypercalcaemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 1994; 57:301-303.
180. Samuel R, Katz K, Papapoulos S, Yosipovitch Z, Zaizov R, Liberman U. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher’s disease. Pediatrics 1994; 94:385-389.
181. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000; 83:143-145.
182. Henderson RC, Lark RK, Kecskemethy H, Miller F, Harcke T, Bachrach S. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141:644-651.
183. Barr RD, Guo CH, Wiernikowski J, Webber C, Wright M, Atkinson S. Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with pamidronate. Med Pediatr Oncol 2002; 39:44-46.
184. Plotkin LI, Parfitt AM, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363-1374.
185. Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 2001; 16:2050-2055.
186. Plotkin H, Bruzoni M, Coughlin S, et al. Low doses of pamidronate for the treatment of osteoporosis in children with cerebral palsy. J Bone Miner Res 2005; 20(suppl 1):S280.
187. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110:1293-1299.
188. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457-463.
189. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab 2003; 16:887-892.
190. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14:529-533.
191. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003; 142:417-423.
192. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20:758-763.
193. Roldan EJA, Perez-Llore, A. Ferretti JL. Olpadronate: a new aminobisphosphonate for the treatment of medical osteopathies. Exp Opin Invest Drugs 1998; 7:1521-1538.
194. Dent CE, Friedman M. Idiopathic Juvenile Osteoporosis. Quat J Med 1965; 134:177-210.
195. Dimar JRN, Campbell M, Glassman SD, Puno RM, Johnson JR. Idiopathic juvenile osteoporosis. An unusual cause of back pain in an adolescent. Am J Orthop 1995; 24:865-869.
196. Villaverde V, De Inocencio J, Merino R, Garcia-Consuegra J. Difficulty walking. A presentation of idiopathic juvenile osteoporosis. J Rheumatol 1998; 25:173-176.
197. Dent CE. Osteoporosis in childhood. Postgrad Med J 1977; 53:450-457.
198. Vela BS, Dorin RI, Hartshorne MF. Case report 631: Neoosseous porosis (metaphyseal osteopenia) in polyglandular autoimmune (Schmidt) syndrome. Skeletal Radiol 1990; 19:468-471.
199. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol 1995; 34:68-77.
200. Child JA, Smith IE. Lymphoma presenting as “idiopathic” juvenile osteoporosis. Br Med J 1975; 29:720-721.
201. Krassas GE. Idiopathic juvenile osteoporosis. Ann NY Acad Sci 2000; 900:409-412.
202. Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH. Deficient bone formation in idiopathic juvenile osteoporosis: a histomorphometric study of cancellous iliac bone. J Bone Miner Res 2000; 15:957-963.
203. Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH. The bone formation defect in idiopathic juvenile osteoporosis is surface-specific. Bone 2002; 31: 85-89.
204. Jackson EC, Strife CF, Tsang RC, Marder HK. Effect of calcitonin replacement therapy in idiopathic juvenile osteoporosis. Am J Dis Child 1988; 142:1237-1239.
205. Glorieux FH, Norman NE, Travers R, Taylor A. Idiopathic juvenile osteoporosis. Hong Kong: Fourth International Symposium on Osteoporosis, 1993:200-202.
206. Saggese G, Bertelloni S, Baroncelli GI, Perri G, Calderazzi A. Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis. Am J Dis Child 1991; 145:457-462.
207. Papapoulos SE. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. 1996:1209-1234.
208. Rosen MG, Dickinson JC. The incidence of cerebral palsy. Am J Obstet Gynecol 1992; 167:417-423.
209. Chapchal G. Damages to bone caused by immobilization and their prevention. J Int Coll Surg 1965; 44:664-667.
210. Takata S, Yasui N. Disuse osteoporosis. J Med Invest 2001; 48:147-156.
211. Schiessl H, Frost HM, Jee WS. Estrogen and bone-muscle strength and mass relationships. Bone 1998; 22:1-6.
212. Klein G. Metabolic bone disease of total parenteral nutrition. Nutrition 1998; 14:149-152.
213. Leonberg BL, Chuang E, Eicher P, Tershakovec AM, Leonard L, Stallings VA. Long-term growth and development in children after home parental nutrition. J Pediatr 1998; 132:461-466.
214. Buchman AL, Moukarzel A. Metabolic bone disease associated with total parenteral nutrition. Clin Nutr 2000; 19:217-231.
215. Mokarzel A. Metabolic bone disease in total parenteral nutrition. In: Lifshitz F, ed. Pediatric Endocrinology. 3rd. New York: Marcel Dekker, 1992:535-545.
216. Dellert SF, Farrell MK, Specker BL, Heubi JE. Bone mineral content in children with short bowel syndrome after discontinuation of parental nutrition. J Pediatr 1998; 132(3 Pt 1):516-519.
217. Cassinelli H, Plotkin H. Bone mineral density for height is normal in patients with growth hormone deficiency and Turner syndrome. Horm Res 2005; 64:82.
218. Cancer Gaspar E, Ruiz-Echarri Zelaya M, Labarta Aizpun JI, Mayayo Dehesa E, Ferrandez Longas A. Study of bone mass in patients with growth hormone deficiency. Am Pediatr (Barc) 2005; 63:219-223.
219. Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab 1993; 76(4):861-866.
220. Lanes R, Gunczler P, Paoli M, Weisinger JR. Bone mineral density of prepubertal age girls with Turner’s syndrome while on growth hormone therapy. Horm Res 1995; 44:168-171.
221. Hogler W, Briody J, Moore B, Garnett S, Lu PW, Cowell CT. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J Clin Endocrinol Metab 2004; 89:193-199.
222. Helenius I, Jalanko H, Remes V, et al. Scoliosis after solid organ transplantation in children and adolescents. Am J Transplant 2006; 6:324-330.
223. Kinugasa A, Fujita K, Inoue F, Kodo N, Sawada T. A case of osteogenesis imperfecta type 1A with an increased frequency of bone fracture after growth hormone therapy. Acta Pediatr Scand 1991; 379(suppl):559-560.
224. Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: are fractures and growth hormone treatment linked? J Pediatr 1998; 132:559-560.
225. Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129:432-439.
226. Frost HM. Bone “mass” and the “mechanostat”: a proposal. Anat Rec 1987; 219:1-9.
227. Frost HM, Ferretti JL, Jee WSS. Prospectives: some roles of mechanical usage, muscle strength, and the mechanostat in skeletal physiology, disease, and research (editorial). Calcif Tissue Int 1998; 62:1-7.
228. Ferretti JL, Cointry GR, Capozza RF, Frost HM. Bone mass, bone strength, muscle-bone interactions, osteopenias and osteoporoses. Mech Ageing Dev 2003; 124:269-279.
229. Sugiyama T, Yamaguchi A, Kawai S. Effects of skeletal loading on bone mass and compensation mechanism in bone: a new insight into the “mechanostat” theory. J Bone Miner Metab 2002; 20:196-200.
230. Newacheck P, Taylor WR. Childhood chronic illness: prevalence, severity, and impact. Am J Pub Health 1992; 82:364-371.
231. Henderson RC. Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia. Dev Med Child Neurol 1997; 39:224-227.
232. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000; 42:816-824.
233. Bottos M, Granato T, Allibrio G, Gioachin C, Puata ML. Prevalence of cerebral palsy in north-east Italy from 1965 to 1989. Dev Med Child Neurol 1999; 41:26-39.
234. Plotkin H, Coughlin S, Kreikemeier R, et al. Low doses of pamidronate for the treatment of osteopenia in children with severe cerebral palsy. Dev Med Child Neurol 2006; 48(9):709-712.
235. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000; 71-74.
236. Aparicio LF, Jurkovic M, DeLullo J. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J Pediatr Orthop 2002; 22:179-181.
237. Bianchi ML, Mazzanti A, Galbiati E, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003; 14(9):761-767.
238. Bothwell JE, Gordon KE, Dooley JM, MacSween J, Cummings EA, Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 2003; 42:353-356.
239. Pascual J, Argente J, Lopez MB, et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 1998; 62:31-35.
240. Valerioa G, del Puente A, Esposito-del Puente A, Buonoc P, Mozzilloc E, Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 2002; 58:266-272.
241. Piepkorn B, Kann P, Forst T, Andreas J, Pfutzner A, Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997; 29:584-591.
242. Lettgen B, Hauffa B, Mohlmann C, Jeken C, Reiners C. Bone mineral density in children and adolescents with juvenile diabetes: selective measurement of bone mineral density of trabecular and cortical bone using peripheral quantitative computed tomography. Horm Res 1995; 43:173-175.
243. Roe TF, Mora S, Costin G, Kaufman F, Carlson ME, Gilsanz V. Vertebral bone density in insulin-dependent diabetic children. Metabolism 1991; 40:967-971.
244. Weger W, Kotanko P, Weger M, Deutschmann H, Skrabal F. Prevalence and characterization of renal tubular acidosis in patients with osteopenia and osteoporosis and in non-porotic controls. Nephrol Dial Transplant 2000; 15:975-980.
245. Gulati S, Godbole M, Singh U, Gulati K, Srivastava A. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J Kidney Dis 2003; 41: 1163-1169.
246. Acott PD, Crocker JF, Wong JA. Decreased bone mineral density in the pediatric renal transplant population. Pediatr Transplant 2003; 7:358-363.
247. el-Husseini AA, el-Agroudy AE, Sobh MA, Ghoneim MA. Bone loss in pediatric renal transplant recipients. Nefrologia 2003; 23(suppl 2):131-134.
248. Rothstein M, Obialo C, Hruska KA. Renal tubular acidosis. Endocrinol Metab Clin North Am 1990; 19:869-887.
249. Chesney RW, Kaplan BS, Phelps M, DeLuca HF. Renal tubular acidosis does not alter circulating values of calcitriol. J Pediatr 1984; 104-last page?
250. Wrong OM, Norden AG, Feest TG. Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. Quat J Med 1994; 87:473-493.
251. Anglani F, Bernich P, Tosetto E, et al. Family history may be misleading in the diagnosis of Dent’s disease. Urol Res 2006; 34:61-63.
252. Burk CD, Restaino I, Kaplan BS, Meadows AT. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 1990; 117:331-335.
253. Segal LS, Palumbo RC, Robertson WWJ. The development of rickets as a complication of chemotherapy for the treatment of Wilms’ tumor. Orthopedics 1995; 18:261-264.
254. Redfield VA, Mimouni F, Strife FC, Tsang RC. Severe rickets in Lowe syndrome: treatment with continuous nasogastric infusion. Pediatr Nephrol 1991; 5:696-699.
255. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi’s syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479-490.
256. Davies MC, Gulekli B, Jacobs HS. Osteoporosis in Turner’s syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf) 1995; 43:741-746.
257. Kazis K, Iglesias E. The female athlete triad. Adolesc Med 2003; 14(1):87-95.
258. Eliakim A, Beyth Y. Exercise training, menstrual irregularities and bone development in children and adolescents. J Pediatr Adolesc Gynecol 2003; 16:201-206.
259. VestergaardP, EmborgC, StovingRK, HagenC, MosekildeL, Brixen K. Patients with eating disorders. A high-risk group for fractures. Orthop Nurs 2003; 22:325-331.
260. Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol 2003; 15:377-384.
261. Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics 1998; 102:481-485.
262. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study. J Clin Endocrinol Metab 2002; 87:2798-2808.
263. Shore RM, Chesney RW, Mazess RB, Rose PG, Bargman GJ. Skeletal demineralization in Turner’s syndrome. Calcif Tissue Int 1982; 34:519-522.
264. Ross JL, Long LM, Feuillan P, Cassorla F, Cutler GB Jr. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J Clin Endocrinol Metab 1991; 73:355-359.
265. Shaw NJ, Rehan VK, Husain S, Marshall T, Smith CS. Bone mineral density in Turner’s syndrome: a longitudinal study. Clin Endocrinol (Oxf) 1997; 47(3):367-370.
266. Nanao K, Tsuchiya Y, Kotoh S, Hasegawa Y. Low vertebral cancellous bone density in peripubertal girls with Turner’s syndrome and boys with hypogonadism. J Pediatr Endocrinol Metab 2002; 15:1537-1542.
267. Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K, Christiansen JS. Increased fracture rates in Turner’s syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 2003; 59:89-96.
268. Stepan JJ, Musilova J, Pacovsky V. Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner’s syndrome. J Bone Miner Res 1989; 4:193-198.
269. Naeraa RW, Brixen K, Hansen RM, et al. Skeletal size and bone mineral content in Turner’s syndrome: relation to karyotype, estrogen treatment, physical fitness, and bone turnover. Calcif Tissue Int 1991; 49:77-83.
270. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241:84-86.
271. Drinkwater BL, Bruemner B, Chesnut CHI. Menstrual history as a determinant of current bone density in young athletes. JAMA 1990; 263:545-548.
272. Vestergaard P, Kristensen K, Bruun JM, et al. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index-a cross-sectional study. J Pediatr 2004; 144:614-619.
273. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992; 74:118-123.
274. Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84:1919-1924.
275. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004; 89:1124-1130.
276. Bouillon R, Koledova E, Bezlepkina O, et al. Bone status and fracture prevalence in Russian adults with childhood onset growth hormone deficiency. J Clin Endocrinol Metab 2004; 89:4993-4998.
277. Sylvester FA. Bone abnormalities in gastrointestinal and hepatic disease. Curr Opin Pediatr 1999; 11:402-407.
278. Mora S, Barera G, Ricotti A, Weber G, Bianchi C, Chiumello G. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am J Clin Nutr 1998; 67:477-481.
279. Kavak US, Yuce A, Kocak N, et al. Bone mineral density in children with untreated and treated celiac disease. J Pediatr Gastroenterol Nutr 2003; 37:434-436.
280. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993; 48:589-593.
281. Bhudhikanok GS, Lim J, Marcus R, Harkins A, Moss RB, Bachrach LK. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics 1996; 97:103-111.
282. West J, Logan RF, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 2003; 125:429-436.
283. Scolapio JS, DeArment J, Hurley DL, Romano M, Harnois D, Weigand SD. Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation. J Parenter Enteral Nutr 2003; 27:427-432.
284. Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F. Bone disorders in cholestatic liver diseases. Forum (Genova) 1998; 8(1):28-38.
285. Klein GL, Soriano H, Shulman RJ, Levy M, Jones G, Langman CB. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 2002; 6(2):136-140.
286. Ng TMH, Bajjoka IE. Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation. Ann Pharmacother 1999; 33:233-235.
287. Gibbens DT, Gilsanz V, Boechat MI, Dufer D, Carlson ME, Wang CI. Osteoporosis in cystic fibrosis. J Pediatr 1988; 113:295-300.
288. Reiter EO, Brugman SM, Pike JW, et al. Vitamin D metabolites in adolescents and young adults with cystic fibrosis: effects of sun and season. J Pediatr 1985; 106: 21-26.
289. Salamoni F, Roulet M, Gudinchet F, Pilet M, Thiebaud D, Burckhardt P. Bone mineral content in cystic fibrosis patients: correlation with fat-free mass. Arch Dis Child 1996; 74(4):314-318.
290. Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr 1996; 128:28-34.
291. Hoffmann GF, Nyhan W, Zschocke J, Kahler SG, Mayatepek E. Storage disorders. In: Inherited Metabolic Diseases. Philadelphia: Lippincott Williams & Wilkins, 2002: 344-356.
292. Lee FA, Donnell GN, Gwinn JL. Radiographic features of fucosidosis. Pediatr Radiol 1977; 5:204-208.
293. Crandall BF, Philippart M, Brown WJ, Bluestone DA. Review article: mucolipidosis IV. Am J Med Genet 1982; 12:301-308.
294. Groen JJ. Present status of knowledge of Gaucher’s disease. Isr J Med Sci 1965; 1:507-510.
295. Beutler E. Gaucher disease. Blood Rev 1988; 2:59-70.
296. Brautbar A, Elstein D, Abrahamov A, et al. The 1604A (R496H) mutation in Gaucher disease: genotype/phenotype correlation. Blood Cells Mol Dis 2003; 31:187-189.
297. Ginns EI, Choudary PV, Tsuji S, et al.Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease. Proc Natl Acad Sci USA 1985; 82:7101-7105.
298. Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 2003; 143:273-276.
299. Mignot C, Gelot A, Bessieres B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet 2003; 120:338-344.
300. Katz K, Cohen IJ, Ziv N, Grunebaum M, Zaizov R, Yosipovitch Z. Fractures in children who have Gaucher disease. J Bone Joint Surg Am 1987; 69:1361-1370.
301. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. Quat J Med 1997; 90(1):19-25.
302. Perheentupa J, Simell O. Lysinuric protein intolerance. Birth Defects Orig Artic Ser 1974; 10:201-207.
303. Svedstrom E, Parto K, Marttinen M, Virtama P, Simell O. Skeletal manifestations of lysinuric protein intolerance. A follow-up study of 29 patients. Skeletal Radiol 1993; 22:11-16.
304. Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE. Lysinuric protein intolerance. Am J Med 1975; 59:229-240.
305. Simell O. Diamino acid transport into granulocytes and liver slices of patients with lysinuric protein intolerance. Pediatr Res 1975; 9:504-508.
306. Smith DW, Scriver CR, Tenenhouse HS, Simell O. Lysinuric protein intolerance mutation is expressed in the plasma membrane of cultured skin fibroblasts. Proc Natl Acad Sci USA 1987; 84:7711-7715.
307. Rajantie J, Simell O, Rapola J, Perheentupa J. Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine. J Pediatr 1980; 97:932-937.
308. Lukkarinen M, Nanto-Salonen K, Pulkki K, Aalto M, Simell O. Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance. Metabolism 2003; 52:935-938.
309. Allen JR, Humphries IR, Waters DL, et al. Decreased bone mineral density in children with phenylketonuria. Am J Clin Nutr 1994; 59:419-422.
310. Zeman J, Bayer M, Stepan J. Bone mineral density in patients with phenylketonuria. Acta Paediatr 1999; 88: 1348-1351.
311. Hillman L, Schlotzhauer C, Lee D, et al. Decreased bone mineralization in children with phenylketonuria under treatment. Eur J Pediatr 1996; 155(suppl 1):S148-S152.
312. Arikoski P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20:234-240.
313. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999; 84:3174-3181.
314. Shalet SM. Endocrine consequences of treatment of malignant disease. Arch Dis Child 1989; 64:1635-1641.
315. Leiper A.Management of growth failure in the treatment of malignant disease. Paed Haematol Oncol 1990; 7:365-371.
316. Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C. Bone mass after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2001; 37:518-524.
317. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hospinks Hosp 1932; 50:137-195.
318. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326:1473-1479.
319. Dempster D. Bone histomorphometry in glucocorticoidinduced osteoporosis. J Bone Miner Res 1989; 4:137-141.
320. Kim HKW, Popp DJ, Hunter DD. Shouldn’t ischemic necrosis of femoral head be called ischemic necrosis and apoptosis of femoral head? J Bone Miner Res 2001; 16(suppl 1):S224.
321. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonateinduced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109:1041-1048.
322. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effect on bone. J Clin Invest 1998; 102:274-282.
323. Weinstein RS. Anatomic juxtaposition of apoptotic osteocytes and avascular necrosis in femurs from patients with glucocorticoid excess. Bone 1998; 23(suppl):S461.
324. van Staa TP, Bishop N, Leufkens HG, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004; 15:785-791.
325. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18:913-918.
326. Liu RH, Albrecht J, Werth VP. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006; 142:37-41.
327. Brinker MR, Thomas KA, Meyers SJ, et al. Bone mineral density of the lumbar spine and proximal femur is decreased in children with sickle cell anemia. Am J Orthop 1998; 27:43-49.
328. Soliman AT, Bererhi H, Darwish A, Alzalabani MM, Wali Y, Ansari B. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr 1998; 44:194-198.
329. Heaney RP, Skillman TG. Calcium metabolism in normal human pregnancy. J Clin Endocrinol Metab 1971; 33: 661-670.
330. Ziegler EE, O’DonnellAM, Nelson SE, Fomon SJ. Body composition of the reference fetus. Growth 1976; 40:329-341.
331. Pelegano JF, Rowe JC, Carey DE, et al. Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ratio. J Pediatr 1989; 114:115-119.
332. Prestridge LL, Schanler RJ, Shulman RJ, Burns PA, Laine LL. Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants. J Pediatr 1993; 122:761-768.
333. Demarini S. Calcium and phosphorus nutrition in preterm infants. Acta Paediatr 2005; 94:87-92.
334. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9(suppl 6):33-35.
335. Celiker R, Bal S, Bakkaloglu A, et al. Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis. Rheumatol Int 2003; 127-129.
336. Cimaz R. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Pract Res Clin Rheumatol 2002; 16:397-409.
337. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16:361-378.
338. Haugen M, Lien G, Flato B, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthr Rheum 2000; 1504-1510.
339. Maenpaa HM, Soini I, Lehto MU, Belt EA. Insufficiency fractures in patients with chronic inflammatory joint diseases. Clin Exp Rheumatol 2002; 20:77-79.
340. Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161:71-77.
341. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177:379-383.
342. Wawrzynska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33:64-67.
343. Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in longterm, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996; 132:184-187.
344. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 13-16.
345. Stanisavljevic S, Babcock AL. Fractures in children treated with methotrexate for leukemia. Clin Orthop 1977; 125: 139-144.
346. Lequin MH, van der Shuis IM, Van Rijn RR, et al. Bone mineral assessment with tibial ultrasonometry and dualenergy X-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood. J Clin Densitom 2002; 5:167-173.
347. Tillmann V, Darlington AS, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res 2002; 17:1073-1080.
348. Warner JT, Evans WD, Webb DK, Bell W, Gregory JW. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res 1999; 45:544-551.
349. Caulton JM, Ward KA, Alsop CW, Dunn G, Adams JE, Mughal MZ. A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy. Arch Dis Child 2004; 89:131-135.
350. Orcel P, Beaudreuil J. Bisphosphonates in bone diseases other than osteoporosis. Joint Bone Spine 2002; 69:19-27.
351. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Pediatr Child Health 2003; 39:88-92.
352. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebocontrolled study. Lancet 2004; 363:1427-1431.
353. Falcini F, Trapani S, Civinini R, Capone A, Ermini M, Bartolozzi G. The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. J Endocrinol Invest 1996; 19:165-169.
354. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children -a prospective multicenter study. Arthr Rheum 2000; 43:1960-1966.
355. Holick MF. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis. South Med J 2005; 98:1114-1117.
356. Plotkin H, Gundberg C, Mitnick M, Stewart AF. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormonerelated peptide (1-36) in humans: potential as an anabolic therapy for osteoporosis. JCEM 1998; 83:2786-2791.
357. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286(5446):1946-1949.